| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Carl H Sadowsky | |
| George T Grossberg | |||
| Drew M Velting | |||
| Joseph L Micca | |||
| P2860 | cites work | Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study | Q44310051 |
| Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. | Q45939476 | ||
| Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. | Q45988408 | ||
| Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study | Q46193667 | ||
| Drug utilization review of cholinesterase inhibitors in Quebec | Q46273913 | ||
| Rivastigmine exposure provided by a transdermal patch versus capsules. | Q46900675 | ||
| Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study | Q48095687 | ||
| Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease | Q48439989 | ||
| Treatment of Alzheimer disease. | Q51004554 | ||
| Measurement of quality-of-life changes in patients with Alzheimer's disease. | Q53189115 | ||
| A new rating scale for Alzheimer's disease. | Q53197509 | ||
| Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. | Q53219308 | ||
| Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. | Q53386775 | ||
| A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule | Q56637378 | ||
| Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications | Q58748657 | ||
| Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease | Q59313801 | ||
| Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease | Q82758614 | ||
| Pharmacogenomic protocols in CNS disorders and dementia | Q83106914 | ||
| “Mini-mental state” | Q25938989 | ||
| Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial | Q28343193 | ||
| Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients | Q33715239 | ||
| The tolerability and safety of cholinesterase inhibitors in the treatment of dementia | Q33960410 | ||
| Rivastigmine for dementia associated with Parkinson's disease | Q33983707 | ||
| Guidelines for managing Alzheimer's disease: Part II. Treatment. | Q34135609 | ||
| Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors | Q34142818 | ||
| Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. | Q34320961 | ||
| An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. | Q34433716 | ||
| A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia | Q34521949 | ||
| Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review | Q36045044 | ||
| Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. | Q36226630 | ||
| Alzheimer's disease and its treatment with a novel transdermal patch therapy: survey of caregiver experiences | Q36419735 | ||
| Transdermal treatment options for neurological disorders: impact on the elderly | Q36528732 | ||
| A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch | Q36950585 | ||
| A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia | Q36998823 | ||
| Treatment of Alzheimer's disease across the spectrum of severity | Q37017375 | ||
| Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings | Q37200827 | ||
| Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review | Q37325828 | ||
| Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease | Q37448875 | ||
| Skin tolerability associated with transdermal drug delivery systems: an overview | Q37646404 | ||
| Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease | Q37725119 | ||
| The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 | ||
| Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. | Q39764934 | ||
| Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models | Q39837265 | ||
| The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease | Q42912221 | ||
| P433 | issue | 5 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| dementia | Q83030 | ||
| Alzheimer's disease | Q11081 | ||
| P577 | publication date | 2014-09-04 | |
| P1433 | published in | The primary care companion for CNS disorders | Q26853834 |
| P1476 | title | Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia | |
| P478 | volume | 16 |
| Q36372148 | A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer's disease treated with rivastigmine transdermal patch |
| Q50328399 | An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine. |
| Q36925905 | Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease |
| Q92320526 | Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study |
| Q61456161 | Influence of Acetylcholinesterase Inhibitors Used in Alzheimer's Disease Treatment on the Activity of Antioxidant Enzymes and the Concentration of Glutathione in Macrophages under Fluoride-Induced Oxidative Stress |
| Q38806392 | Potential applications of stress solutes from extremophiles in protein folding diseases and healthcare |
| Q33596451 | Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia |
| Q40074585 | Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study |
Search more.